SCHEMBL7326682

SCHEMBL7326682

CCN(CCCc1ccc(C2CCCCC2)c(Cl)c1)C1CCCCC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 12/20 0.57
TMEM97 Q5BJF2 1/20 0.57
EBP Q15125 1/20 0.57
CYP2D6 P10635 2/20 0.40
TSHR P16473 2/20 0.40
CYP2C9 P11712 1/20 0.40
GRIN2B Q13224 2/20 0.39
ALDH1A1 P00352 2/20 0.37
MAPT P10636 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
OPRK1 P41145 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C19 P33261 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
BCHE P06276 1/20 0.36
NUDT1 P36639 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL9152015 0.99 SIGMAR1 (0.56) SIGMAR1TMEM97EBPCYP2D6TSHR
Hydrochloric Acid SCHEMBL7512083 0.87 SIGMAR1 (0.44) SIGMAR1TMEM97EBPCYP2D6TSHR
SCHEMBL11633835 0.86 SIGMAR1 (0.46) SIGMAR1TMEM97EBPCYP2D6TSHR
Hydrochloric Acid SCHEMBL30343200 0.85 SIGMAR1 (0.45) SIGMAR1TMEM97EBPCYP2D6TSHR
SCHEMBL11632591 0.83 SIGMAR1 (0.43) SIGMAR1TMEM97EBPCYP2D6TSHR
SCHEMBL8327379 0.79 SPHK1 (0.48) GRIN2BALDH1A1
SCHEMBL26765560 0.77 SIGMAR1 (0.56) SIGMAR1TMEM97EBPCYP2D6TSHR
SCHEMBL7314582 0.77 SIGMAR1 (0.61) SIGMAR1TMEM97EBPGRIN2BBCHE
Hydrochloric Acid SCHEMBL9152388 0.76 SIGMAR1 (0.55) SIGMAR1TMEM97EBPCYP2D6TSHR
SCHEMBL29412737 0.76 SIGMAR1 (0.47) SIGMAR1TMEM97ALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230364033-A1 COMPOUNDS FOR TREATING VIRUS INFECTIONS MELETIOS THERAPEUTICS (FR) 2023-11-16 US disclosed
US-20230364033-A1 COMPOUNDS FOR TREATING VIRUS INFECTIONS MELETIOS THERAPEUTICS (FR) 2023-11-16 US disclosed
US-20230364033-A1 COMPOUNDS FOR TREATING VIRUS INFECTIONS MELETIOS THERAPEUTICS (FR) 2023-11-16 US disclosed
EP-4213822-A1 COMPOUNDS FOR TREATING VIRUS INFECTIONS MELETIOS Therapeutics (FR) 2023-07-26 EP disclosed
WO-2022058533-A1 COMPOUNDS FOR TREATING VIRUS INFECTIONS MELETIOS THERAPEUTICS (FR) 2022-03-24 WO disclosed
US-6235791-B1 USING CIS N-CYCLOHEXYL-N-ETHYL(3-(3-CHLORO-CYCLOHEXYLPHENYL)ALLYL)AMINE SANOFI-SYNTHELABO (FR) 2001-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230364033-A1 COMPOUNDS FOR TREATING VIRUS INFECTIONS ACE, HAVCR2, FURIN SIGMAR1 3429/4885TMEM97 3055/4885EBP 660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.